EHMT2 Knockout NCI-H1703 Polyclonal Cells represent a CRISPR/Cas9-mediated polyclonal knockout cell population targeting the EHMT2 gene in the NCI-H1703 human lung squamous cell carcinoma line. This loss-of-function model was generated by disrupting EHMT2 via CRISPR/Cas9 genome editing, yielding a heterogeneous pool of edited cells suitable for functional studies of EHMT2-dependent epigenetic regulation. The polyclonal format captures a broad spectrum of gene-disruption events, enabling robust assessment of population-level phenotypes without clonal selection artifacts.
The parental NCI-H1703 cell line was originally established from a lung tumor of a 54-year-old male patient with squamous cell carcinoma. These adherent epithelial cells display classic morphological features of squamous carcinoma and are widely employed in preclinical oncology research to model lung cancer biology, drug response, and metastasis. Their genomic and transcriptomic profiles reflect the mutational burden and signaling alterations characteristic of lung squamous cell carcinoma, providing a clinically relevant context for EHMT2 perturbation.
EHMT2 (G9a) functions as a histone methyltransferase that catalyzes mono- and dimethylation of histone H3 at lysine 9 (H3K9me1/me2), a hallmark of repressive chromatin. EHMT2 is transcriptionally regulated by SOX2, MYC, and E2F1, and its activity can be modulated by hypoxia via HIF1A and AKT signaling. The enzyme directly interacts with HP1 proteins (CBX1, CBX3, CBX5), DNMT1, DNMT3A, UHRF1, and components of the PRC2 complex, such as EZH2, to coordinate stable gene silencing. Downstream, EHMT2 represses key targets including the cyclin-dependent kinase inhibitor CDKN1A (p21), the adhesion molecule CDH1 (E-cadherin), and additional tumor suppressor loci, thereby promoting proliferation and invasive behavior.
In the NCI-H1703 background, EHMT2 is frequently upregulated and contributes to the malignant phenotype by maintaining silencing of tumor suppressors and epithelial differentiation genes. Disruption of EHMT2 in these polyclonal KO cells is expected to reduce H3K9me1/me2 levels, relieve transcriptional repression, and impair oncogenic properties such as proliferation and migration. Consequently, this model serves as a powerful tool for dissecting the epigenetic circuitry that sustains squamous cell carcinoma and for evaluating strategies aimed at reactivating silenced gene expression programs.
Researchers can utilize these cells in diverse experimental workflows: western blotting and immunofluorescence to assess H3K9me1/me2 changes; ChIP-qPCR to quantify H3K9me2 occupancy at target promoters; RT-qPCR and RNA-seq to profile transcriptional derepression; and functional assays to measure cell proliferation, migration, and drug sensitivity. The model is particularly suited for validating EHMT2 inhibitors and exploring crosstalk with Wnt and Notch pathways. For technical inquiries, please contact Ascent Research.
